MTD201

MTD201 is a sustained-release microparticle formulation of octreotide, a somatostatin analogue, developed using the proprietary Q-Sphera technology. It was designed by Midatech Pharma (now Biodexa Pharmaceuticals) for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. The Q-Sphera platform utilizes 3D printing-like techniques to create uniform polymer microspheres that encapsulate the active drug, allowing for a controlled, long-acting release profile. Clinical data suggested that MTD201 could maintain therapeutic plasma concentrations of octreotide with an injection interval of six to eight weeks, potentially offering a more convenient dosing schedule than existing monthly treatments. However, in March 2020, Midatech terminated internal development of the program to preserve capital, making the asset available for external licensing.

Other names

Octreotide Q-Sphera